Literature DB >> 16109105

A Clinico-pathological study on the effect of vincristine on transmissible venereal tumour in dogs.

D Nak1, Y Nak, I T Cangul, B Tuna.   

Abstract

Transmissible venereal tumour (TVT) is a coitally transmitted neoplasm of dogs and is common among sexually active dogs, where sexual behaviour is not under control. Several treatment options are available for the treatment of the tumour, with chemotherapy being the most commonly employed. In this study, we investigated the clinical and cytological changes after weekly vincristine sulphate administration in 38 cases of naturally occurring TVT. Tumours totally regressed in 31 dogs after two to seven doses (mean 3.54 +/- 1.01) of vincristine. One dog died after the fifth dose of vincristine, and in six dogs, an additional treatment with doxorubicin was needed. Masses were still present in four dogs and the histopathological examination revealed small nodules of granulation tissue in two dogs, while viable tumour cells were identified in the remaining two cases. No recurrences were observed in a follow-up period of 7-49 months (mean 13.64 +/- 9.66); in one dog, granulation tissue was detected in the surgery site after 2 months. Treatment success could easily be followed by the cytological changes. In conclusion, vincristine was found to be effective chemotherapeutic agent.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109105     DOI: 10.1111/j.1439-0442.2005.00743.x

Source DB:  PubMed          Journal:  J Vet Med A Physiol Pathol Clin Med        ISSN: 0931-184X


  10 in total

1.  A case of ocular canine transmissible venereal tumor.

Authors:  Jewel Milo; Elisabeth Snead
Journal:  Can Vet J       Date:  2014-01       Impact factor: 1.008

2.  To lose both would look like carelessness: Tasmanian devil facial tumour disease.

Authors:  Hamish McCallum; Menna Jones
Journal:  PLoS Biol       Date:  2006-10       Impact factor: 8.029

3.  Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT).

Authors:  Supannika Hantrakul; Narumol Klangkaew; Sunee Kunakornsawat; Tawewan Tansatit; Ammart Poapolathep; Susumu Kumagai; Saranya Poapolathep
Journal:  J Vet Med Sci       Date:  2014-08-21       Impact factor: 1.267

4.  Transrectal ultrasound-integrated spectral optical tomography of hypoxic progression of a regressing tumor in a canine prostate.

Authors:  Z Jiang; D Piao; K E Bartels; G R Holyoak; J W Ritchey; C L Ownby; K Rock; G Slobodov
Journal:  Technol Cancer Res Treat       Date:  2011-12

5.  The changing global distribution and prevalence of canine transmissible venereal tumour.

Authors:  Andrea Strakova; Elizabeth P Murchison
Journal:  BMC Vet Res       Date:  2014-09-03       Impact factor: 2.741

6.  Intratumoral recombinant human interferon alpha-2a and vincristine combination therapy in canine transmissible venereal tumour.

Authors:  Halit Kanca; Gizem Tez; Kazim Bal; Dogukan Ozen; Eray Alcigir; Sevil Atalay Vural
Journal:  Vet Med Sci       Date:  2018-08-17

7.  Relationship between plasma cell-free DNA changes and lysyl oxidase during the treatment and prognosis of canine transmissible venereal tumors.

Authors:  Mona Mohamadzaheri; Hadi Cheraghi; Darioush Shirani; Ali Hatamkhani
Journal:  BMC Vet Res       Date:  2022-02-21       Impact factor: 2.741

8.  Successful management and recovery of a dog with immune-mediated thrombocytopenia following vincristine overdose.

Authors:  Maude Poirier; April E Blong; Rebecca A L Walton
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2022-02-07

9.  Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumor model of chemoresistance: Sticker sarcoma.

Authors:  Enrico P Spugnini; Ivan Dotsinsky; Nikolay Mudrov; Gennaro Citro; Alfredo D'Avino; Alfonso Baldi
Journal:  J Exp Clin Cancer Res       Date:  2008-11-03

10.  Detection of progressive and regressive phase and LINE-1 retrotransposon in transfected dogs with transmissible venereal tumor during chemotherapy.

Authors:  Sevil Atalay Vural; Rifki Haziroglu; Mehmet R Vural; Ibrahim M Polat; Arda S Tunc
Journal:  J Vet Sci       Date:  2018-09-30       Impact factor: 1.672

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.